CJH Stock Overview
Develops, manufactures, and commercializes vaccines in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CanSino Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.78 |
| 52 Week High | HK$3.84 |
| 52 Week Low | HK$1.85 |
| Beta | 0.46 |
| 11 Month Change | 20.38% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -76.19% |
| 5 Year Change | -31.27% |
| Change since IPO | -20.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| CJH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 20.4% | 1.5% | 3.2% |
| 1Y | n/a | -14.5% | 9.7% |
Return vs Industry: Insufficient data to determine how CJH performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how CJH performed against the German Market.
Price Volatility
| CJH volatility | |
|---|---|
| CJH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CJH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine CJH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,149 | Xuefeng Yu | www.cansinotech.com |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Inc. Fundamentals Summary
| CJH fundamental statistics | |
|---|---|
| Market cap | €1.58b |
| Earnings (TTM) | -€93.78m |
| Revenue (TTM) | €97.48m |
10.2x
P/S Ratio-10.6x
P/E RatioIs CJH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CJH income statement (TTM) | |
|---|---|
| Revenue | CN¥748.53m |
| Cost of Revenue | CN¥774.40m |
| Gross Profit | -CN¥25.87m |
| Other Expenses | CN¥694.25m |
| Earnings | -CN¥720.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.91 |
| Gross Margin | -3.46% |
| Net Profit Margin | -96.20% |
| Debt/Equity Ratio | 41.3% |
How did CJH perform over the long term?
See historical performance and comparison